Project Grant R43CA295307
Award Date
9/10/24
Completion Date
8/31/25
Dollars Obligated
$399K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Mountain View, CA 94043, USA
Similar Awards
Cordance Medical Inc. received a $998,501 cooperative agreement award from the National Science Foundation under the Engineering program (CFDA 47.041) for the period of July 15, 2021 through June 30, 2023. The award will support Cordance Medical's efforts to develop transcranial dynamic focused ultrasound for the non-invasive opening of the blood-brain barrier, allowing targeted delivery of therapeutic agents to the brain. The Engineering program seeks to improve quality of life and economic...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $2,278,167 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to the University of North Carolina at Chapel Hill (UNC-CH) and the California Institute of Technology (Caltech). The grant aims to develop non-invasive, ultra-high precision transcranial ultrasound surgery techniques for treating brain tumors, such as glioblastoma...
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $163,640 to the University of Virginia to develop novel non-viral gene delivery platforms for the treatment of glioblastoma, an aggressive brain cancer. The research aims to improve the therapeutic accumulation and delivery of gene therapies by leveraging brain-penetrating nanoparticles and focused ultrasound technology. Key objectives include investigating the tumor-targeting and...
The National Cancer Institute (NCI) awarded a $1,200,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The funded research aims to target the extracellular glucose-regulated protein 78 (eGRP78) expressed on the surface of drug-resistant tumor cells, in order to induce apoptosis, eliminate drug and immune resistance, and reduce the...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the federal Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is funding the development of a Transcranial Magnetic Resonance (MR) and Ultrasound (US) Guided Histotripsy (TCMR-USGHT) system for the non-invasive treatment of brain tumors. The $543,959 award to the Regents of the University of Michigan aims to advance this novel...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $252,370 to the University of Maryland, Baltimore to evaluate the use of focused ultrasound and immunoPET imaging to enhance the delivery and effects of the anti-CD47 immunotherapy in a clinically representative animal model of glioblastoma. The central hypothesis is that the focused ultrasound will augment the delivery and immunomodulatory effects of the anti-CD47 monoclonal antibody in...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $244,839 to the University of Virginia to investigate the use of magnetic resonance imaging-guided focused ultrasound (MRGFUS) to enhance chimeric antigen receptor (CAR) T cell therapy for the treatment of medulloblastoma, an aggressive pediatric brain cancer. The key objectives are to evaluate the synergistic effects of MRGFUS and CAR T cell therapy in...
The National Cancer Institute (NCI) awarded a $679,176 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of Texas at Dallas (UTD) to develop a novel and minimally invasive method to enhance spinal cord delivery of cancer therapies. The key products and services to be delivered under this 5-year award include: Characterizing the blood-spinal cord barrier (BSCB) and utilizing epidural light-based techniques (OptoBSCB) to temporarily and...